

# Omid Tavana

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1629608/publications.pdf>

Version: 2024-02-01

26  
papers

2,114  
citations

567281

15  
h-index

580821

25  
g-index

26  
all docs

26  
docs citations

26  
times ranked

3078  
citing authors

#	ARTICLE	IF	CITATIONS
1	ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway. <i>Nature Cell Biology</i> , 2019, 21, 579-591.	10.3	486
2	p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast Cancer. <i>Cancer Cell</i> , 2012, 21, 793-806.	16.8	279
3	The Deubiquitylase OTUB1 Mediates Ferroptosis via Stabilization of SLC7A11. <i>Cancer Research</i> , 2019, 79, 1913-1924.	0.9	263
4	p53 modifications: exquisite decorations of the powerful guardian. <i>Journal of Molecular Cell Biology</i> , 2019, 11, 564-577.	3.3	260
5	NRF2 Is a Major Target of ARF in p53-Independent Tumor Suppression. <i>Molecular Cell</i> , 2017, 68, 224-232.e4.	9.7	219
6	HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma. <i>Nature Medicine</i> , 2016, 22, 1180-1186.	30.7	158
7	Modulation of the p53/MDM2 interplay by HAUSP inhibitors. <i>Journal of Molecular Cell Biology</i> , 2017, 9, 45-52.	3.3	75
8	Absence of p53-dependent apoptosis leads to UV radiation hypersensitivity, enhanced immunosuppression and cellular senescence. <i>Cell Cycle</i> , 2010, 9, 3348-3356.	2.6	50
9	Absence of p53-Dependent Apoptosis Combined With Nonhomologous End-Joining Deficiency Leads to a Severe Diabetic Phenotype in Mice. <i>Diabetes</i> , 2010, 59, 135-142.	0.6	46
10	AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia. <i>Clinical Cancer Research</i> , 2020, 26, 6535-6549.	7.0	42
11	The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets. <i>Nature Cancer</i> , 2021, 2, 1406-1422.	13.2	33
12	Too many breaks (brakes): Pancreatic $\beta$ -cell senescence leads to diabetes. <i>Cell Cycle</i> , 2011, 10, 2471-2484.	2.6	29
13	Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 10460-10473.	6.4	28
14	Deciphering the acetylation code of p53 in transcription regulation and tumor suppression. <i>Oncogene</i> , 2022, 41, 3039-3050.	5.9	20
15	Peli1 Modulates the Subcellular Localization and Activity of Mdmx. <i>Cancer Research</i> , 2018, 78, 2897-2910.	0.9	18
16	Targeting HAUSP in both p53 wildtype and p53-mutant tumors. <i>Cell Cycle</i> , 2018, 17, 823-828.	2.6	17
17	Independent functions of DNMT1 and USP7 at replication foci. <i>Epigenetics and Chromatin</i> , 2018, 11, 9.	3.9	17
18	The Hunger Games: p53 Regulates Metabolism upon Serine Starvation. <i>Cell Metabolism</i> , 2013, 17, 159-161.	16.2	15

#	ARTICLE	IF	CITATIONS
19	Systematic illumination of druggable genes in cancer genomes. <i>Cell Reports</i> , 2022, 38, 110400.	6.4	14
20	Ku70 Functions in Addition to Nonhomologous End Joining in Pancreatic $\beta^2$ -Cells. <i>Diabetes</i> , 2013, 62, 2429-2438.	0.6	12
21	The "readers" of unacetylated p53 represent a new class of acidic domain proteins. <i>Nucleus</i> , 2017, 8, 360-369.	2.2	12
22	ARF "NRF2: A new checkpoint for oxidative stress responses?. <i>Molecular and Cellular Oncology</i> , 2018, 5, e1432256.	0.7	11
23	p53 and DNA methylation suppress the TRAIN to cell death. <i>Cell Cycle</i> , 2013, 12, 9-10.	2.6	4
24	Controlling ARF stability. <i>Cell Cycle</i> , 2014, 13, 497-498.	2.6	3
25	Systematic Pan-Cancer Characterization of Nuclear Receptors Identifies Potential Cancer Biomarkers and Therapeutic Targets. <i>Cancer Research</i> , 2022, 82, 46-59.	0.9	3
26	Combination of AZD4573, a Selective CDK9 Inhibitor, with Other Cell Death Inducing Agents Can Overcome De Novo Venetoclax Resistance in Preclinical Hematologic Tumor Models. <i>Blood</i> , 2018, 132, 3946-3946.	1.4	0